IL3RA and myelodysplastic syndrome: Phase I/II trial is being evaluated in R/R AML and high-risk MDS patients (NCT02152956) to further assess the efficacy of flotetuzumab therapy; (ii) XmAb14045 (SQZ622) is another CD123 x CD3 bsAb.